Unlimited Bio News

Unlimited Bio Partners with Artgen Biotech to Advance VEGF Plasmid Gene Therapy

May 13, 2024 — UnlimitedBio on X

Unlimited Bio has entered into a strategic partnership with Artgen Biotech, the manufacturer of the world’s first approved VEGF plasmid gene therapy, to explore new applications of VEGF in cosmetic and regenerative medicine.

“We are excited to explore the potential of VEGF to become the first genetic therapy for cosmetic indications,” the company announced.

What Is VEGF Gene Therapy?

VEGF (Vascular Endothelial Growth Factor) stimulates the formation of new blood vessels, improving tissue oxygenation, nutrient delivery, and regeneration — all critical processes that decline with age.

Clinical studies show that VEGF plasmid therapy can:

  • Increase capillary density in treated muscle tissue.
  • Improve blood flow and endurance in patients with Peripheral Artery Disease (PAD).
  • Support tissue repair and skin rejuvenation through enhanced microcirculation.

Toward the First Genetic Aesthetic Treatment

Unlimited Bio aims to validate VEGF for cosmetic and wellness indications, such as:

  • Enhanced skin vascularization and tone,
  • Hair regrowth through improved scalp perfusion,
  • Muscle rejuvenation and recovery.

This collaboration positions Unlimited Bio at the frontier of regenerative aesthetics, where gene therapy meets longevity science.